Skip to content
MedsAcross

Medicine

Nalbuphine 20 mg/1 mL injection

Nalbuphine · Intramuscular, intravenous, subcutaneous
Available on requestPrescription onlyUS FDAGeneric name

Nalbuphine 20 mg/1 mL injection is a generic prescription medicine for intramuscular, intravenous, subcutaneous use, made by 2 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store at 20℃ to 25°C (68℉ to 77°F). Protect from excessive light. Store in…

Key facts

Active ingredient (INN)
Nalbuphine
Brand
Sold under the generic name
Strength
20 mg/1 mL
Dosage form
Injection
Route
Intramuscular, intravenous, subcutaneous
Packs
10 ampules of 1 mL
Manufacturers
HospiraSomerset Therapeutics
Origin register
US FDA, United States
Storage
Store at 20℃ to 25°C (68℉ to 77°F). Protect from excessive light. Store in carton until contents have been used.
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
N02AF02 Nalbuphine
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
31 December 2004
Identifiers
RxCUI 904415, 904440, 1866543 +1DailyMed set ID 6025e8d4-5083-4c3a-58a0-050e7b0b6150, a3221c05-5822-4ab8-b589-0e3939b91a68NDC 0409-1465, 70069-672Application ANDA070916, ANDA216050

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

Packs from every labeler of this generic presentation.

PackCodeLabelerMarketed since
10 ampule in 1 tray / 1 mL in 1 ampule0409-1465-01Hospira31 December 2004
10 ampule in 1 carton / 1 mL in 1 ampule70069-672-10Somerset Therapeutics25 September 2024

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 15 May 1979Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Other strengths and forms of Nalbuphine

Clinical summary

Nalbuphine is an opioid agonist/antagonist indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. It is available as injection for intramuscular, intravenous and subcutaneous use. MedsAcross supplies Nalbuphine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Nalbuphine

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Nalbuphine 20 mg/1 mL injection for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.